TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35398501

Group type: EXPERIMENTAL
Intervention: AnluoHuaxian pill (AHP)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 34812521

Group type: EXPERIMENTAL
Intervention: Fit2Thrive core intervention (self-monitoring app and Fitbit)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Fit2Thrive core intervention with support calls, buddy, and text messages (on level)
Number of subjects: 269
Study: 33970187

Group type: EXPERIMENTAL
Intervention: Preterm formula powder (PTF)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Human milk fortifier (HMF)
Number of subjects: 123
Study: 32798689

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 139

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 139
Study: 37937943

Group type: EXPERIMENTAL
Intervention: Clinical protocol informed by an arterial waveform contour analysis monitor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 32990608

Group type: EXPERIMENTAL
Intervention: 200 g of tomato juice
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 200 g of tomato
Number of subjects: 25

Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 25
Study: 33775981

Group type: EXPERIMENTAL
Intervention: PVI-alone strategy
Number of subjects: 496

Group type: COMPARATOR
Intervention: PVI-plus strategy
Number of subjects: 496
Study: 32955841

Group type: EXPERIMENTAL
Intervention: Hatha yoga-based training program (HY)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study: 34157925

Group type: EXPERIMENTAL
Intervention: HTO-arthroscopy (HTO-A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: HTO
Number of subjects: 82
Study: 34346027

Group type: EXPERIMENTAL
Intervention: ESP block
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: TLIP block
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study: 35842288

Group type: EXPERIMENTAL
Intervention: Labtician BlephaDex (BD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OCuSOFT Oust Demodex (OD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Théa Blephademodex (BDdx)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: I‐MED I‐Lid'n Lash Plus (ILL+)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chrissanthe Eye Cleanse (EC)
Number of subjects: 30
Study: 34491340

Group type: EXPERIMENTAL
Intervention: Conventional treatment for T2DM plus training in diaphragmatic breathing and systematic relaxation for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment for T2DM
Number of subjects: 100
Study: 36522207

Group type: EXPERIMENTAL
Intervention: European regimen (group 1): vincristine, ifosfamide, doxorubicin, and etoposide induction, and consolidation using vincristine, actinomycin D, with ifosfamide or cyclophosphamide, or busulfan and melphalan.
Number of subjects: 640

Group type: COMPARATOR
Intervention: US regimen (group 2): vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide induction, plus ifosfamide and etoposide, and consolidation using vincristine and cyclophosphamide, or vincristine, actinomycin D, and ifosfamide, with busulfan and melphalan.
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: European regimen (group 1)
Number of subjects: 640

Group type: COMPARATOR
Intervention: US regimen (group 2)
Number of subjects: 640
Study: 33522444

Group type: EXPERIMENTAL
Intervention: Goal management training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 35586621

Group type: EXPERIMENTAL
Intervention: Extra-Virgin Olive Oil + Traditional Brazilian Diet (OliveOil+DietBra)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extra-Virgin Olive Oil only
Number of subjects: 40
Study: 34925655

Group type: EXPERIMENTAL
Intervention: E-learning module
Number of subjects: 201

Group type: COMPARATOR
Intervention: Small-group lecture
Number of subjects: 201
Study: 35605902

Group type: EXPERIMENTAL
Intervention: Anodal tDCS before motor practice (tDCSbefore)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anodal tDCS during motor practice (tDCSduring)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anodal tDCS after motor practice (tDCSafter)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with motor practice (CONmp)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without motor practice (CON)
Number of subjects: 100
Study: 33604735

Group type: EXPERIMENTAL
Intervention: Contralateral (CL) ACLR using semitendinosus (ST) graft from the contralateral leg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ipsilateral (IL) ACLR using semitendinosus (ST) graft from the ipsilateral leg
Number of subjects: 140
Study: 33864164

Group type: EXPERIMENTAL
Intervention: Breast Cancer Recurrence instrument (BreastCaRe)
Number of subjects: 1170
Study: 32453913

Group type: EXPERIMENTAL
Intervention: Febuxostat (120 mg for 4 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Allopurinol (300 mg for 7 days)
Number of subjects: 10
Study: 36413385

Group type: EXPERIMENTAL
Intervention: 4-week internet-delivered mindfulness-based cancer recovery (iMBCR) program
Number of subjects: 103

Group type: COMPARATOR
Intervention: usual care and 4-week program of health education information (control group)
Number of subjects: 103
Study: 35312441

Group type: EXPERIMENTAL
Intervention: IM20 × 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IM60 × 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: IM20 × 3
Number of subjects: 0
Study: 32487102

Group type: EXPERIMENTAL
Intervention: Erenumab (monthly for 6 months)
Number of subjects: 162
Study: 36397217

Group type: EXPERIMENTAL
Intervention: Acupuncture+rTMS combination group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: rTMS combination group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medication group (escitalopram oxalate)
Number of subjects: 90
Study: 32895196

Group type: EXPERIMENTAL
Intervention: LTD4-BPT
Number of subjects: 151

Group type: COMPARATOR
Intervention: MCH-BPT
Number of subjects: 151
Study: 35090162

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cerebral transit time
Number of subjects: 18
Study: 33632189

Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal block (RIB) with 20-mL 0.375% ropivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal block with sub-serratus plane block (RISS) using a total of 40-mL 0.375% ropivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (C) - no block intervention
Number of subjects: 90
Study: 32804661

Group type: EXPERIMENTAL
Intervention: Autologous cultured epidermal cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-cultured autologous skin cell suspensions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split-thickness skin autografts (STSGs)
Number of subjects: 0
Study: 33837571

Group type: EXPERIMENTAL
Intervention: PMS50 supplementation (550 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 34426527

Group type: EXPERIMENTAL
Intervention: MEEi <0.34 mL/s per gram
Number of subjects: 1703

Group type: EXPERIMENTAL
Intervention: MEEi
Number of subjects: 1703
Study: 35140339

Group type: EXPERIMENTAL
Intervention: Two courses of DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 5 days) every 3 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Three courses of DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 5 days) every 3 weeks
Number of subjects: 180
Study: 34308314

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day for 12 weeks
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 153
Study: 35164698

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (n=20), 40 min/session, at least 4 times/week for 12 weeks, with protein supplementation (9 g/day).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n=20), received exercise instruction without active encouragement and continuous monitoring, with protein supplementation (9 g/day).
Number of subjects: 40
Study: 32674235

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation combined with enteral nutrition (EN group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional nutrition (Con group)
Number of subjects: 150
Study: 33025835

Group type: EXPERIMENTAL
Intervention: Parents as Teachers with Smart Parents‐Safe and Healthy Kids (PAT+SPSHK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parents as Teachers as usual (PAT‐AU)
Number of subjects: 0
Study: 34646753

Group type: EXPERIMENTAL
Intervention: Online psychological intervention (8 modules based on motivational interviewing and cognitive-behavioral therapy, with weekly therapeutic support via phone calls lasting a maximum of 10 minutes)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Online psychological intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 134
Study: 36114133

Group type: EXPERIMENTAL
Intervention: Cardioneuroablation (CNA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Optimal nonpharmacologic therapy (Control)
Number of subjects: 48
Study: 33559439

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with ibuprofen sustained‐release capsule
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ibuprofen sustained‐release capsule
Number of subjects: 144
Study: 35257652

Group type: EXPERIMENTAL
Intervention: Social network-based supportive program (WhatsApp)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 33568703

Group type: EXPERIMENTAL
Intervention: Charged DNA rods at low ionic strengths (below 1-2 mM salt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various experimental methods (image-time correlation, microscopic dynamics in small angle dynamic light scattering, optical activity in second harmonic generation, differential scanning calorimetry)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiral pitches of the N* phase
Number of subjects: 0
Study: 32568651

Group type: EXPERIMENTAL
Intervention: 220 mg of intravenous theophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35292925

Group type: EXPERIMENTAL
Intervention: Bumetanide (oral liquid formulation 0.5 mg bid)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 33682043

Group type: EXPERIMENTAL
Intervention: Thermal innocuous stimuli
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Thermal noxious stimuli
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mechanical innocuous stimuli
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mechanical noxious stimuli
Number of subjects: 19
Study: 32352368

Group type: EXPERIMENTAL
Intervention: Suspension formulation (test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granule formulation (reference)
Number of subjects: 0
Study: 35078446

Group type: EXPERIMENTAL
Intervention: SOAR knee health program (exercise-based program)
Number of subjects: 70
Study: 34890212

Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 4482

Group type: EXPERIMENTAL
Intervention: Complete remission (CR)
Number of subjects: 4482
Study: 33766922

Group type: EXPERIMENTAL
Intervention: PCI of culprit and non-culprit lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culprit lesion-only PCI
Number of subjects: 0
Study: 32719263

Group type: EXPERIMENTAL
Intervention: Extraoral approach of GNB with 4 mL of 0.5% bupivacaine and 40 mg of triamcinolonacetonide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraoral approach of GNB with 4 mL of 0.5% bupivacaine and 40 mg of triamcinolonacetonide
Number of subjects: 50
Study: 34302609

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone spray + oral betamethasone (0.1 mg/kg per day for 7 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intranasal beclomethasone spray only
Number of subjects: 28
Study: 33392871

Group type: EXPERIMENTAL
Intervention: Omecamtiv in heart failure with reduced ejection fraction (GALACTIC-HF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotagliflozin in patients with diabetes and recent heart failure exacerbation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia (STRENGTH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids in elderly patients with recent myocardial infarction (OMEMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evinacumab in patients with refractory hypercholesterolemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography for assessment of suspected acute coronary syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polypill for primary prevention of cardiovascular disease in intermediate-risk people (International Polycaps Study - TIPS-3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAMSON trial - three-arm-N-of-1 trial for patient nonadherence to statin therapy
Number of subjects: 0
Study: 35370766

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT; n = 7)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sensorimotor Training (SMT; n = 10)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (CG; n = 7)
Number of subjects: 24
Study: 32519140

Group type: EXPERIMENTAL
Intervention: IBGard™
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34988975

Group type: EXPERIMENTAL
Intervention: Topical 5% 5-fluorouracil (5-FU)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod (IMIQ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sunscreen (sun-protective factor 30+)
Number of subjects: 40
Study: 33555418

Group type: EXPERIMENTAL
Intervention: Intensive statin (rosuvastatin 20 mg daily × 14 days)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control (rosuvastatin 5 mg daily × 14 days)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Intensive statin
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control
Number of subjects: 310
Study: 32830164

Group type: EXPERIMENTAL
Intervention: AWL treated with resin infiltration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AWL treated with resin infiltration and 5,000 cycles of thermocycling
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AWL treated with resin infiltration and 10,000 cycles of thermocycling
Number of subjects: 50

Group type: COMPARATOR
Intervention: AWL with no treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sound teeth (Group 1)
Number of subjects: 50
Study: 35746502

Group type: EXPERIMENTAL
Intervention: EV71 vaccine administered simultaneously with other vaccines
Number of subjects: 1080

Group type: COMPARATOR
Intervention: EV71 vaccine separate administration group
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: All groups (simultaneous and separate administration)
Number of subjects: 1080
Study: 33144512

Group type: EXPERIMENTAL
Intervention: Very Early Mobilization (VEM)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2104
Study: 34343599

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study: 34509800

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 26004
Study: 35237159

Group type: EXPERIMENTAL
Intervention: Yunpi Qufeng Chushi formula (YQCF)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 32525743

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet score and Alternative Healthy Eating Index
Number of subjects: 9724

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 9724
Study: 35597443

Group type: COMPARATOR
Intervention: Control group (no disinfection)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ozonated water (O3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rose Bengal (RB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ti-sapphire laser
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ammonium Hexafluorosilicate (NH4)2[SiF6]
Number of subjects: 100
Study: 33818780

Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg before erenumab 140 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg after galcanezumab 240 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs) with ubrogepant coadministered with erenumab or galcanezumab
Number of subjects: 40
Study: 35916348

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg
Number of subjects: 3488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3488
Study: 32366927

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (SIL, 50 mg twice daily)
Number of subjects: 50
Study: 36345026

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group (no GnRHa)
Number of subjects: 311
Study: 33444458

Group type: EXPERIMENTAL
Intervention: Individualized yoga intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: iPad control program
Number of subjects: 6
Study: 33971211

Group type: EXPERIMENTAL
Intervention: Sun safety intervention (exact details not specified)
Number of subjects: 3710

Group type: COMPARATOR
Intervention: Observation-only control group
Number of subjects: 3710
Study: 34391418

Group type: EXPERIMENTAL
Intervention: 5 days of glucocorticoid treatment
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 14 days of glucocorticoid treatment
Number of subjects: 178
Study: 32603993

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline predictors (including pretreatment worry scores, number of comorbid conditions, hypertension, working memory task scores, hippocampal volumes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working memory tasks
Number of subjects: 0
Study: 35144636

Group type: EXPERIMENTAL
Intervention: Fenofibrate therapy (n=2673)
Number of subjects: 5340

Group type: COMPARATOR
Intervention: Placebo (n=2667)
Number of subjects: 5340

Group type: EXPERIMENTAL
Intervention: Minimum LDL-C during follow-up
Number of subjects: 5340

Group type: EXPERIMENTAL
Intervention: Visit-to-visit LDL-C variability
Number of subjects: 5340
Study: 34537830

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study: 34824052

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 36103174

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33630160

Group type: EXPERIMENTAL
Intervention: −50% ICM reduction models
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: −80% ICM reduction models
Number of subjects: 85
Study: 32958718

Group type: EXPERIMENTAL
Intervention: Early favipiravir therapy (starting on day 1)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Late favipiravir therapy (starting on day 6)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Favipiravir (both early and late)
Number of subjects: 89
Study: 35253571

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine before stenting
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 228
Study: 32993343

Group type: EXPERIMENTAL
Intervention: Vitamin E-doped polyethylene (vE-PE) liner
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard cross-linked polyethylene (XLPE) liner
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 32 mm femoral head
Number of subjects: 127

Group type: COMPARATOR
Intervention: 36 mm femoral head
Number of subjects: 127
Study: 33813328

Group type: EXPERIMENTAL
Intervention: Osimertinib monotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Osimertinib plus carboplatin-pemetrexed combination therapy
Number of subjects: 62
Study: 32426889

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1660
Study: 36029642

Group type: EXPERIMENTAL
Intervention: SB fading manipulation
Number of subjects: 115

Group type: COMPARATOR
Intervention: No-instruction control
Number of subjects: 115
Study: 33367744

Group type: EXPERIMENTAL
Intervention: Fulacimstat 25 mg twice daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fulacimstat
Number of subjects: 147
Study: 32253520

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 6 weeks, load adjusted to 40% of maximal inspiratory pressure
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo control group (CG) for 6 weeks, load adjusted to a minimum placebo load (9 cm H2O)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo control group (CG)
Number of subjects: 31
Study: 35168906

Group type: EXPERIMENTAL
Intervention: Trainee guided simulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unsupervised group
Number of subjects: 100
Study: 33989990

Group type: EXPERIMENTAL
Intervention: Manual therapy based on articulatory techniques
Number of subjects: 50
Study: 34763534

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure at five specific acupressure points (1 min/point, twice a day for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-specific acupressure at five non-specific acupressure points (1 min/point, twice a day for 4 weeks)
Number of subjects: 15
Study: 34507586

Group type: EXPERIMENTAL
Intervention: Vegan meal (V)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional meal (M)
Number of subjects: 40
Study: 36474344

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 30 days
Number of subjects: 228

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily for 30 days
Number of subjects: 228
Study: 33303457

Group type: EXPERIMENTAL
Intervention: Intranasal Ketodex (combination of dexmedetomidine and ketamine)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Intravenous ketamine
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Intranasal Ketodex
Number of subjects: 410